Dr. Tony Holohan:

That is one question on which NIAC is advising and it probably would not be wise of me to guess, but there was a strong case for boosting the entire population in the way that we have. It looks to us as though the third dose that people got as a booster was important in restoring, in particular, some of the lost protection against severe infection. We think that is likely to hold up pretty well now and the same case may not exist for boosting the entire population. It may well be the case there will be a focus on people who are vulnerable, although I am not predicting that. NIAC will be independent in respect of the advice it gives us but, as the Chairman suggested, there is a likelihood we might move on from that recommendation that informed the first booster campaign and not necessarily assume there will be another round of booster doses at a defined interval. That is exactly the question on which NIAC is focused at the moment.